Soleno Therapeutics Inc [SLNO] stock is trading at $62.74, up 1.01%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SLNO shares have gain 4.36% over the last week, with a monthly amount drifted -10.64%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Soleno Therapeutics Inc [NASDAQ: SLNO] stock has seen the most recent analyst activity on October 07, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $125. Previously, Wells Fargo started tracking the stock with Overweight rating on August 20, 2025, and set its price target to $123. On June 23, 2025, TD Cowen initiated with a Buy rating and assigned a price target of $110 on the stock. Stifel reiterated its recommendation of a Buy but $74 remained the price target by the analyst firm on December 02, 2024. Robert W. Baird reiterated a Outperform rating for this stock on December 02, 2024, but kept the price target unchanged to $72. In a note dated September 03, 2024, H.C. Wainwright initiated an Buy rating and provided a target price of $70 on this stock.
Soleno Therapeutics Inc [SLNO] stock has fluctuated between $41.50 and $90.32 over the past year. Currently, Wall Street analysts expect the stock to reach $123 within the next 12 months. Soleno Therapeutics Inc [NASDAQ: SLNO] shares were valued at $62.74 at the most recent close of the market. An investor can expect a potential return of 96.05% based on the average SLNO price forecast.
Analyzing the SLNO fundamentals
Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -5.87%, Pretax Profit Margin comes in at -5.54%, and Net Profit Margin reading is -5.54%. To continue investigating profitability, this company’s Return on Assets is posted at -0.54, Equity is -0.74 and Total Capital is -0.62. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 60.15 points at the first support level, and at 57.57 for the second support level. However, for the 1st resistance point, the stock is sitting at 64.85, and for the 2nd resistance point, it is at 66.97.
Ratios To Look Out For
For context, Soleno Therapeutics Inc’s Current Ratio is 15.13. Further, the Quick Ratio stands at 15.01, while the Cash Ratio is 3.65. Considering the valuation of this stock, the price to sales ratio is 102.09, the price to book ratio is 13.18.
Transactions by insiders
Recent insider trading involved Abingworth Bioventures VII LP, Shareholder, that happened on Aug 11 ’25 when 1.35 million shares were purchased. SEE REMARKS, Hirano Patricia C completed a deal on Jul 01 ’25 to sell 3830.0 shares. Meanwhile, Officer PATRICIA HIRANO bought 3830.0 shares on Jul 01 ’25.
